Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 342

1.

The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer.

Kryza T, Bock N, Lovell S, Rockstroh A, Lehman ML, Lesner A, Panchadsaram J, Silva LM, Srinivasan S, Snell CE, Williams ED, Fazli L, Gleave M, Batra J, Nelson C, Tate EW, Harris J, Hooper JD, Clements JA.

Mol Oncol. 2019 Oct 20. doi: 10.1002/1878-0261.12587. [Epub ahead of print]

2.

Microenvironment engineering of osteoblastic bone metastases reveals osteomimicry of patient-derived prostate cancer xenografts.

Shokoohmand A, Ren J, Baldwin J, Atack A, Shafiee A, Theodoropoulos C, Wille ML, Tran PA, Bray LJ, Smith D, Chetty N, Pollock PM, Hutmacher DW, Clements JA, Williams ED, Bock N.

Biomaterials. 2019 Nov;220:119402. doi: 10.1016/j.biomaterials.2019.119402. Epub 2019 Jul 31.

PMID:
31400612
3.

Constraints to counting bioluminescence producing cells by a commonly used transgene promoter and its implications for experimental design.

Mosaad EO, Futrega K, Seim I, Gloss B, Chambers KF, Clements JA, Doran MR.

Sci Rep. 2019 Aug 5;9(1):11334. doi: 10.1038/s41598-019-46916-z.

4.

Emergence of MicroRNAs as Key Players in Cancer Cell Metabolism.

Subramaniam S, Jeet V, Clements JA, Gunter JH, Batra J.

Clin Chem. 2019 Sep;65(9):1090-1101. doi: 10.1373/clinchem.2018.299651. Epub 2019 May 17. Review.

PMID:
31101638
5.

Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment.

Bock N, Shokoohmand A, Kryza T, Röhl J, Meijer J, Tran PA, Nelson CC, Clements JA, Hutmacher DW.

Bone Res. 2019 Apr 25;7:13. doi: 10.1038/s41413-019-0049-8. eCollection 2019.

6.

MicroRNA-3162-5p-Mediated Crosstalk between Kallikrein Family Members Including Prostate-Specific Antigen in Prostate Cancer.

Matin F, Jeet V, Srinivasan S, Cristino AS, Panchadsaram J, Clements JA, Batra J; Australian Prostate Cancer BioResource.

Clin Chem. 2019 Jun;65(6):771-780. doi: 10.1373/clinchem.2018.295824. Epub 2019 Apr 24.

PMID:
31018918
7.

Gamma-Tocotrienol Induces Apoptosis in Prostate Cancer Cells by Targeting the Ang-1/Tie-2 Signalling Pathway.

Tang KD, Liu J, Russell PJ, Clements JA, Ling MT.

Int J Mol Sci. 2019 Mar 7;20(5). pii: E1164. doi: 10.3390/ijms20051164.

8.

Integration of Two In-depth Quantitative Proteomics Approaches Determines the Kallikrein-related Peptidase 7 (KLK7) Degradome in Ovarian Cancer Cell Secretome.

Silva LM, Kryza T, Stoll T, Hoogland C, Dong Y, Stephens CR, Hastie ML, Magdolen V, Kleifeld O, Gorman JJ, Clements JA.

Mol Cell Proteomics. 2019 May;18(5):818-836. doi: 10.1074/mcp.RA118.001304. Epub 2019 Jan 31.

PMID:
30705123
9.

Humanization of the Prostate Microenvironment Reduces Homing of PC3 Prostate Cancer Cells to Human Tissue-Engineered Bone.

McGovern JA, Shafiee A, Wagner F, Lahr CA, Landgraf M, Meinert C, Williams ED, Russell PJ, Clements JA, Loessner D, Holzapfel BM, Risbridger GP, Hutmacher DW.

Cancers (Basel). 2018 Nov 13;10(11). pii: E438. doi: 10.3390/cancers10110438.

10.

A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns.

Loessner D, Rockstroh A, Shokoohmand A, Holzapfel BM, Wagner F, Baldwin J, Boxberg M, Schmalfeldt B, Lengyel E, Clements JA, Hutmacher DW.

Biomaterials. 2019 Jan;190-191:63-75. doi: 10.1016/j.biomaterials.2018.10.014. Epub 2018 Oct 16.

PMID:
30396040
11.

Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study.

Adams CD, Richmond R, Ferreira DLS, Spiller W, Tan V, Zheng J, Würtz P, Donovan J, Hamdy F, Neal D, Lane JA, Smith GD, Relton C, Eeles RA, Haiman CA, Kote-Jarai Z, Schumacher FR, Olama AAA, Benlloch S, Muir K, Berndt SI, Conti DV, Wiklund F, Chanock SJ, Gapstur S, Stevens VL, Tangen CM, Batra J, Clements JA, Gronberg H, Pashayan N, Schleutker J, Albanes D, Wolk A, West CML, Mucci LA, Cancel-Tassin G, Koutros S, Sorensen KD, Maehle L, Travis RC, Hamilton RJ, Ingles SA, Rosenstein BS, Lu YJ, Giles GG, Kibel AS, Vega A, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Nordestgaard BG, Brenner H, Maier C, Kim J, John EM, Teixeira MR, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Lessel D, Kaneva RP, Usmani N, Claessens F, Townsend PA, Dominguez MG, Roobol MJ, Menegaux F, Khaw KT, Cannon-Albright LA, Pandha H, Thibodeau SN, Martin RM; PRACTICAL consortium.

Cancer Epidemiol Biomarkers Prev. 2019 Jan;28(1):208-216. doi: 10.1158/1055-9965.EPI-18-0079. Epub 2018 Oct 23.

12.

Association Analysis of a Microsatellite Repeat in the TRIB1 Gene With Prostate Cancer Risk, Aggressiveness and Survival.

Moya L, Lai J, Hoffman A, Srinivasan S, Panchadsaram J, Chambers S, Clements JA, Batra J; Australian Prostate Cancer BioResource.

Front Genet. 2018 Oct 4;9:428. doi: 10.3389/fgene.2018.00428. eCollection 2018.

13.

Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.

Wang P, Magdolen V, Seidl C, Dorn J, Drecoll E, Kotzsch M, Yang F, Schmitt M, Schilling O, Rockstroh A, Clements JA, Loessner D.

Br J Cancer. 2018 Oct;119(7):1-9. doi: 10.1038/s41416-018-0260-1. Epub 2018 Oct 5.

14.

Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer.

Loessner D, Goettig P, Preis S, Felber J, Bronger H, Clements JA, Dorn J, Magdolen V.

Expert Opin Ther Targets. 2018 Sep;22(9):745-763. doi: 10.1080/14728222.2018.1512587. Epub 2018 Sep 6. Review.

PMID:
30114962
15.

Mining human cancer datasets for kallikrein expression in cancer: the 'KLK-CANMAP' Shiny web tool.

Wang C, Moya L, Clements JA, Nelson CC, Batra J.

Biol Chem. 2018 Sep 25;399(9):983-995. doi: 10.1515/hsz-2017-0322.

PMID:
30052511
16.

A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer.

Matin F, Jeet V, Moya L, Selth LA, Chambers S; Australian Prostate Cancer BioResource, Clements JA, Batra J.

Sci Rep. 2018 Apr 27;8(1):6653. doi: 10.1038/s41598-018-24424-w.

17.

Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.

Lophatananon A, Stewart-Brown S, Kote-Jarai Z, Al Olama AA, Garcia SB, Neal DE, Hamdy FC, Donovan JL, Giles GG, Fitzgerald LM, Southey MC, Pharoah P, Pashayan N, Gronberg H, Wiklund F, Aly M, Stanford JL, Brenner H, Dieffenbach AK, Arndt V, Park JY, Lin HY, Sellers T, Slavov C, Kaneva R, Mitev V, Batra J, Spurdle A, Clements JA; APCB BioResource; PRACTICAL consortium, Easton D, Eeles RA, Muir K.

Br J Cancer. 2018 Mar 20;118(6):e16. doi: 10.1038/bjc.2018.6. Epub 2018 Feb 13.

18.

Standard PREanalytical Code version 3.0.

Betsou F, Bilbao R, Case J, Chuaqui R, Clements JA, De Souza Y, De Wilde A, Geiger J, Grizzle W, Guadagni F, Gunter E, Heil S, Kiehntopf M, Koppandi I, Lehmann S, Linsen L, Mackenzie-Dodds J, Aguilar Quesada R, Tebbakha R, Selander T, Shea K, Sobel M, Somiari S, Spyropoulos D, Stone M, Tybring G, Valyi-Nagy K, Wadhwa L.

Biopreserv Biobank. 2018 Jan 29. doi: 10.1089/bio.2017.0109. [Epub ahead of print] No abstract available.

PMID:
29377712
19.

The Microwell-mesh: A high-throughput 3D prostate cancer spheroid and drug-testing platform.

Mosaad EO, Chambers KF, Futrega K, Clements JA, Doran MR.

Sci Rep. 2018 Jan 10;8(1):253. doi: 10.1038/s41598-017-18050-1.

20.

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.

Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Garcia SB, Muir K, Grönberg H, Wiklund F, Aly M, Schleutker J, Sipeky C, Tammela TL, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Cuk K, Saum KU, Park JY, Sellers TA, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Karow DS, Mills IG, Andreassen OA, Dale AM; PRACTICAL Consortium*.

BMJ. 2018 Jan 10;360:j5757. doi: 10.1136/bmj.j5757.

21.

Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases.

Reid JC, Matsika A, Davies CM, He Y, Broomfield A, Bennett NC, Magdolen V, Srinivasan B, Clements JA, Hooper JD.

Am J Cancer Res. 2017 Nov 1;7(11):2257-2274. eCollection 2017.

22.

A microsatellite repeat in PCA3 long non-coding RNA is associated with prostate cancer risk and aggressiveness.

Lai J, Moya L, An J, Hoffman A, Srinivasan S, Panchadsaram J, Walpole C, Perry-Keene JL, Chambers S; Australian Prostate Cancer BioResource, Lehman ML, Nelson CC, Clements JA, Batra J.

Sci Rep. 2017 Dec 4;7(1):16862. doi: 10.1038/s41598-017-16700-y.

23.

Mass spectrometry based proteomics analyses in kallikrein-related peptidase research: implications for cancer research and therapy.

Silva LM, Clements JA.

Expert Rev Proteomics. 2017 Dec;14(12):1119-1130. doi: 10.1080/14789450.2017.1389637. Epub 2017 Oct 17. Review.

PMID:
29025353
24.

Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.

Lophatananon A, Stewart-Brown S, Kote-Jarai Z, Olama AAA, Garcia SB, Neal DE, Hamdy FC, Donovan JL, Giles GG, Fitzgerald LM, Southey MC, Pharoah P, Pashayan N, Gronberg H, Wiklund F, Aly M, Stanford JL, Brenner H, Dieffenbach AK, Arndt V, Park JY, Lin HY, Sellers T, Slavov C, Kaneva R, Mitev V, Batra J, Spurdle A, Clements JA; APCB BioResource; PRACTICAL consortium, Easton D, Eeles RA, Muir K.

Br J Cancer. 2017 Aug 22;117(5):734-743. doi: 10.1038/bjc.2017.231. Epub 2017 Aug 1. Erratum in: Br J Cancer. 2018 Feb 13;:.

25.

Mass spectrometry-based determination of Kallikrein-related peptidase 7 (KLK7) cleavage preferences and subsite dependency.

Silva LM, Stoll T, Kryza T, Stephens CR, Hastie ML, Irving-Rodgers HF, Dong Y, Gorman JJ, Clements JA.

Sci Rep. 2017 Jul 28;7(1):6789. doi: 10.1038/s41598-017-06680-4.

26.

A humanised tissue-engineered bone model allows species-specific breast cancer-related bone metastasis in vivo.

Quent V, Taubenberger AV, Reichert JC, Martine LC, Clements JA, Hutmacher DW, Loessner D.

J Tissue Eng Regen Med. 2018 Feb;12(2):494-504. doi: 10.1002/term.2517. Epub 2017 Nov 29.

PMID:
28714574
27.

Lycopene reduces ovarian tumor growth and intraperitoneal metastatic load.

Holzapfel NP, Shokoohmand A, Wagner F, Landgraf M, Champ S, Holzapfel BM, Clements JA, Hutmacher DW, Loessner D.

Am J Cancer Res. 2017 Jun 1;7(6):1322-1336. eCollection 2017.

28.

Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells.

Kryza T, Silva LM, Bock N, Fuhrman-Luck RA, Stephens CR, Gao J, Samaratunga H; Australian Prostate Cancer BioResource, Lawrence MG, Hooper JD, Dong Y, Risbridger GP, Clements JA.

Mol Oncol. 2017 Oct;11(10):1307-1329. doi: 10.1002/1878-0261.12075. Epub 2017 Aug 10.

29.

Determining Protease Substrates Within a Complex Protein Background Using the PROtein TOpography and Migration Analysis Platform (PROTOMAP).

Fuhrman-Luck RA, Silva LM, Hastie ML, Gorman JJ, Clements JA.

Methods Mol Biol. 2017;1574:145-170. doi: 10.1007/978-1-4939-6850-3_11.

PMID:
28315249
30.

Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum.

de Veer SJ, Furio L, Swedberg JE, Munro CA, Brattsand M, Clements JA, Hovnanian A, Harris JM.

J Invest Dermatol. 2017 Feb;137(2):430-439. doi: 10.1016/j.jid.2016.09.017. Epub 2016 Sep 30.

31.

MicroRNA Theranostics in Prostate Cancer Precision Medicine.

Matin F, Jeet V, Clements JA, Yousef GM, Batra J.

Clin Chem. 2016 Oct;62(10):1318-33. doi: 10.1373/clinchem.2015.242800. Epub 2016 Aug 18. Review.

32.

In vitro evidence that KLK14 regulates the components of the HGF/Met axis, pro-HGF and HGF-activator inhibitor 1A and 1B.

Reid JC, Bennett NC, Stephens CR, Carroll ML, Magdolen V, Clements JA, Hooper JD.

Biol Chem. 2016 Dec 1;397(12):1299-1305. doi: 10.1515/hsz-2016-0163.

PMID:
27533117
33.

Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.

Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, Lawrenson K, Lindstrom S, Ramus SJ, Thompson DJ; ABCTB Investigators, Kibel AS, Dansonka-Mieszkowska A, Michael A, Dieffenbach AK, Gentry-Maharaj A, Whittemore AS, Wolk A, Monteiro A, Peixoto A, Kierzek A, Cox A, Rudolph A, Gonzalez-Neira A, Wu AH, Lindblom A, Swerdlow A; AOCS Study Group & Australian Cancer Study (Ovarian Cancer); APCB BioResource, Ziogas A, Ekici AB, Burwinkel B, Karlan BY, Nordestgaard BG, Blomqvist C, Phelan C, McLean C, Pearce CL, Vachon C, Cybulski C, Slavov C, Stegmaier C, Maier C, Ambrosone CB, Høgdall CK, Teerlink CC, Kang D, Tessier DC, Schaid DJ, Stram DO, Cramer DW, Neal DE, Eccles D, Flesch-Janys D, Edwards DR, Wokozorczyk D, Levine DA, Yannoukakos D, Sawyer EJ, Bandera EV, Poole EM, Goode EL, Khusnutdinova E, Høgdall E, Song F, Bruinsma F, Heitz F, Modugno F, Hamdy FC, Wiklund F, Giles GG, Olsson H, Wildiers H, Ulmer HU, Pandha H, Risch HA, Darabi H, Salvesen HB, Nevanlinna H, Gronberg H, Brenner H, Brauch H, Anton-Culver H, Song H, Lim HY, McNeish I, Campbell I, Vergote I, Gronwald J, Lubiński J, Stanford JL, Benítez J, Doherty JA, Permuth JB, Chang-Claude J, Donovan JL, Dennis J, Schildkraut JM, Schleutker J, Hopper JL, Kupryjanczyk J, Park JY, Figueroa J, Clements JA, Knight JA, Peto J, Cunningham JM, Pow-Sang J, Batra J, Czene K, Lu KH, Herkommer K, Khaw KT; kConFab Investigators, Matsuo K, Muir K, Offitt K, Chen K, Moysich KB, Aittomäki K, Odunsi K, Kiemeney LA, Massuger LF, Fitzgerald LM, Cook LS, Cannon-Albright L, Hooning MJ, Pike MC, Bolla MK, Luedeke M, Teixeira MR, Goodman MT, Schmidt MK, Riggan M, Aly M, Rossing MA, Beckmann MW, Moisse M, Sanderson M, Southey MC, Jones M, Lush M, Hildebrandt MA, Hou MF, Schoemaker MJ, Garcia-Closas M, Bogdanova N, Rahman N; NBCS Investigators, Le ND, Orr N, Wentzensen N, Pashayan N, Peterlongo P, Guénel P, Brennan P, Paulo P, Webb PM, Broberg P, Fasching PA, Devilee P, Wang Q, Cai Q, Li Q, Kaneva R, Butzow R, Kopperud RK, Schmutzler RK, Stephenson RA, MacInnis RJ, Hoover RN, Winqvist R, Ness R, Milne RL, Travis RC, Benlloch S, Olson SH, McDonnell SK, Tworoger SS, Maia S, Berndt S, Lee SC, Teo SH, Thibodeau SN, Bojesen SE, Gapstur SM, Kjær SK, Pejovic T, Tammela TL; GENICA Network; PRACTICAL consortium, Dörk T, Brüning T, Wahlfors T, Key TJ, Edwards TL, Menon U, Hamann U, Mitev V, Kosma VM, Setiawan VW, Kristensen V, Arndt V, Vogel W, Zheng W, Sieh W, Blot WJ, Kluzniak W, Shu XO, Gao YT, Schumacher F, Freedman ML, Berchuck A, Dunning AM, Simard J, Haiman CA, Spurdle A, Sellers TA, Hunter DJ, Henderson BE, Kraft P, Chanock SJ, Couch FJ, Hall P, Gayther SA, Easton DF, Chenevix-Trench G, Eeles R, Pharoah PD, Lambrechts D.

Cancer Discov. 2016 Sep;6(9):1052-67. doi: 10.1158/2159-8290.CD-15-1227. Epub 2016 Jul 17.

34.

Prostate Cancer-Associated Kallikrein-Related Peptidase 4 Activates Matrix Metalloproteinase-1 and Thrombospondin-1.

Fuhrman-Luck RA, Stansfield SH, Stephens CR, Loessner D, Clements JA.

J Proteome Res. 2016 Aug 5;15(8):2466-78. doi: 10.1021/acs.jproteome.5b01148. Epub 2016 Jul 27.

PMID:
27378148
35.

A computational analysis of the genetic and transcript diversity at the kallikrein locus.

Lai J, An J, Srinivasan S, Clements JA, Batra J.

Biol Chem. 2016 Dec 1;397(12):1307-1313. doi: 10.1515/hsz-2016-0161.

PMID:
27289002
36.

Erratum to: Fusion transcript loci share many genomic features with non-fusion loci.

Lai J, An J, Seim I, Walpole C, Hoffman A, Moya L, Srinivasan S, Perry-Keene JL; Australian Prostate Cancer Bioresource, Wang C, Lehman ML, Nelson CC, Clements JA, Batra J.

BMC Genomics. 2016 Jun 3;17(1):424. No abstract available.

37.

Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation.

Gusev A, Shi H, Kichaev G, Pomerantz M, Li F, Long HW, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Zheng W, Pettaway CA, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, John EM, Murphy AB, Signorello LB, Carpten J, Leske MC, Wu SY, Hennis AJ, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Witte JS, Casey G, Kaggwa S, Cook MB, Stram DO, Blot WJ, Eeles RA, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Southey MC, Fitzgerald LM, Gronberg H, Wiklund F, Aly M, Henderson BE, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W, Cannon-Albright L, Teerlink C, Brenner H, Dieffenbach AK, Arndt V, Park JY, Sellers TA, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Spurdle A, Clements JA, Teixeira MR, Pandha H, Michael A, Paulo P, Maia S, Kierzek A; PRACTICAL consortium, Conti DV, Albanes D, Berg C, Berndt SI, Campa D, Crawford ED, Diver WR, Gapstur SM, Gaziano JM, Giovannucci E, Hoover R, Hunter DJ, Johansson M, Kraft P, Le Marchand L, Lindström S, Navarro C, Overvad K, Riboli E, Siddiq A, Stevens VL, Trichopoulos D, Vineis P, Yeager M, Trynka G, Raychaudhuri S, Schumacher FR, Price AL, Freedman ML, Haiman CA, Pasaniuc B.

Nat Commun. 2016 Apr 7;7:10979. doi: 10.1038/ncomms10979.

38.

Lycopene's Effects on Cancer Cell Functions within Monolayer and Spheroid Cultures.

Holzapfel NP, Holzapfel BM, Theodoropoulos C, Kaemmerer E, Rausch T, Feldthusen J, Champ S, Clements JA, Hutmacher DW, Loessner D.

Nutr Cancer. 2016;68(2):350-63. doi: 10.1080/01635581.2016.1150498. Epub 2016 Mar 25.

PMID:
27015041
39.

Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors.

de Veer SJ, Swedberg JE, Brattsand M, Clements JA, Harris JM.

Biol Chem. 2016 Dec 1;397(12):1237-1249. doi: 10.1515/hsz-2016-0112.

PMID:
26894578
40.

Adipocytes promote prostate cancer stem cell self-renewal through amplification of the cholecystokinin autocrine loop.

Tang KD, Liu J, Jovanovic L, An J, Hill MM, Vela I, Lee TK, Ma S, Nelson C, Russell PJ, Clements JA, Ling MT.

Oncotarget. 2016 Jan 26;7(4):4939-48. doi: 10.18632/oncotarget.6643.

41.

Fusion transcript loci share many genomic features with non-fusion loci.

Lai J, An J, Seim I, Walpole C, Hoffman A, Moya L, Srinivasan S, Perry-Keene JL; Australian Prostate Cancer Bioresource, Wang C, Lehman ML, Nelson CC, Clements JA, Batra J.

BMC Genomics. 2015 Dec 1;16:1021. doi: 10.1186/s12864-015-2235-4. Erratum in: BMC Genomics. 2016;17:424.

42.

Hypermethylation of the 5' CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis.

Manton KJ, Douglas ML, Netzel-Arnett S, Fitzpatrick DR, Nicol DL, Boyd AW, Clements JA, Antalis TM.

Br J Cancer. 2015 Dec 1;113(11):1640. doi: 10.1038/bjc.2015.384. No abstract available.

43.

Single nucleotide polymorphisms in clinics: Fantasy or reality for cancer?

Srinivasan S, Clements JA, Batra J.

Crit Rev Clin Lab Sci. 2016;53(1):29-39. doi: 10.3109/10408363.2015.1075469. Epub 2015 Sep 23. Review.

PMID:
26398894
44.

The kallikrein-related peptidase family: Dysregulation and functions during cancer progression.

Kryza T, Silva ML, Loessner D, Heuzé-Vourc'h N, Clements JA.

Biochimie. 2016 Mar;122:283-99. doi: 10.1016/j.biochi.2015.09.002. Epub 2015 Sep 4. Review.

PMID:
26343558
45.

Genome-wide association study of prostate cancer-specific survival.

Szulkin R, Karlsson R, Whitington T, Aly M, Gronberg H, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Southey MC, FitzGerald LM, Henderson BE, Schumacher FR, Haiman CA, Sipeky C, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Lubiński J, Kluźniak W, Cannon-Albright L, Brenner H, Herrmann V, Holleczek B, Park JY, Sellers TA, Lim HY, Slavov C, Kaneva RP, Mitev VI, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A; PRACTICAL consortium, Batra J, Clements JA; Australian Prostate Cancer BioResource, Albanes D, Andriole GL, Berndt SI, Chanock S, Gapstur SM, Giovannucci EL, Hunter DJ, Kraft P, Le Marchand L, Ma J, Mondul AM, Penney KL, Stampfer MJ, Stevens VL, Weinstein SJ, Trichopoulou A, Bueno-de-Mesquita BH, Tjønneland A, Cox DG; BPC3 consortium, Maehle L, Schleutker J, Lindström S, Wiklund F.

Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1796-800. doi: 10.1158/1055-9965.EPI-15-0543. Epub 2015 Aug 25.

46.

Prediction of individual genetic risk to prostate cancer using a polygenic score.

Szulkin R, Whitington T, Eklund M, Aly M, Eeles RA, Easton D, Kote-Jarai ZS, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Southey MC, Fitzgerald LM, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Lubiński J, Kluźniak W, Cannon-Albright L, Brenner H, Butterbach K, Stegmaier C, Park JY, Sellers T, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA; Australian Prostate Cancer BioResource, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A; Practical Consortium, Gronberg H, Wiklund F.

Prostate. 2015 Sep;75(13):1467-74. doi: 10.1002/pros.23037. Epub 2015 Jul 14. Erratum in: Prostate. 2015 Dec;75(16):1972. Lim, Hui-Yi [corrected to Lin, Hui-Yi].

PMID:
26177737
47.

Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.

Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, Benlloch Garcia S, Giles GG, Southey MC, Fitzgerald L, Gronberg H, Wiklund F, Aly M, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, Mcdonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokołorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Butterbach K, Arndt V, Park JY, Sellers T, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Govindasami K, Guy M, Lophatonanon A, Muir K, Viñuela A, Brown AA; PRACTICAL Consortium; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative; Australian Prostate Cancer BioResource; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators, Freedman M, Conti DV, Easton D, Coetzee GA, Eeles RA, Kote-Jarai Z.

Hum Mol Genet. 2015 Oct 1;24(19):5589-602. doi: 10.1093/hmg/ddv203. Epub 2015 May 29.

48.

Tissue engineered humanized bone supports human hematopoiesis in vivo.

Holzapfel BM, Hutmacher DW, Nowlan B, Barbier V, Thibaudeau L, Theodoropoulos C, Hooper JD, Loessner D, Clements JA, Russell PJ, Pettit AR, Winkler IG, Levesque JP.

Biomaterials. 2015 Aug;61:103-14. doi: 10.1016/j.biomaterials.2015.04.057. Epub 2015 May 19.

PMID:
26001075
49.

Tie-2 regulates the stemness and metastatic properties of prostate cancer cells.

Tang KD, Holzapfel BM, Liu J, Lee TK, Ma S, Jovanovic L, An J, Russell PJ, Clements JA, Hutmacher DW, Ling MT.

Oncotarget. 2016 Jan 19;7(3):2572-84. doi: 10.18632/oncotarget.3950.

50.

Correction: 3D Cultures of Prostate Cancer Cells Cultured in a Novel High-Throughput Culture Platform Are More Resistant to Chemotherapeutics Compared to Cells Cultured in Monolayer.

Chambers KF, Mosaad EM, Russell PJ, Clements JA, Doran MR.

PLoS One. 2015 Apr 22;10(4):e0125641. doi: 10.1371/journal.pone.0125641. eCollection 2015. No abstract available.

Supplemental Content

Loading ...
Support Center